{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:11:05Z","timestamp":1791522665172,"version":"4.3.4"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Nonbacteremic community-acquired pneumonia (CAP) is a leading presentation of severe pneumococcal disease in adults. Serotype-specific urinary antigen detection (UAD) assay can detect serotypes causing pneumococcal CAP, including nonbacteremic cases, and guide recommendations for use of higher valency pneumococcal conjugate vaccines (PCVs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adult CAP serotype distribution studies that used both Pfizer UADs (UAD1, detects PCV13 serotypes; UAD2, detects PCV20 non-PCV13 serotypes plus 2, 9N, 17F, and 20) were identified by review of an internal study database and included if results were published. The percentages of all-cause radiologically confirmed CAP (RAD + CAP) due to individual or grouped (PCV13, PCV15, and PCV20) serotypes as detected from culture or UAD were reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Six studies (n = 2, United States; n = 1 each, Germany, Sweden, Spain, and Greece) were included. The percentage of RAD + CAP among adults \u226518 years with PCV13 serotypes equaled 4.6% to 12.9%, with PCV15 serotypes 5.9% to 14.5%, and with PCV20 serotypes 7.8% to 23.8%. The percentage of RAD + CAP due to PCV15 and PCV20 serotypes was 1.1\u20131.3 and 1.3\u20131.8 times higher than PCV13 serotypes, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>PCV13 serotypes remain a cause of RAD + CAP among adults even in settings with pediatric PCV use. Higher valency PCVs among adults could address an important proportion of RAD + CAP in this population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiad379","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T14:32:07Z","timestamp":1693837927000},"page":"282-293","source":"Crossref","is-referenced-by-count":23,"title":["Multicountry Review of <i>Streptococcus pneumoniae<\/i> Serotype Distribution Among Adults With Community-Acquired Pneumonia"],"prefix":"10.1093","volume":"229","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4538-6424","authenticated-orcid":false,"given":"Lindsay R","family":"Grant","sequence":"first","affiliation":[{"name":"Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group , Collegeville, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1287-5416","authenticated-orcid":false,"given":"Elizabeth","family":"Begier","sequence":"additional","affiliation":[{"name":"Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group , Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0821-9202","authenticated-orcid":false,"given":"Christian","family":"Theilacker","sequence":"additional","affiliation":[{"name":"Vaccines, Antivirals, and Evidence Generation, Pfizer Pharma GmbH , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Barry","sequence":"additional","affiliation":[{"name":"Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group , Collegeville, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Hall-Murray","sequence":"additional","affiliation":[{"name":"Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group , Collegeville, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Yan","sequence":"additional","affiliation":[{"name":"Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group , Collegeville, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veneta","family":"Pope","sequence":"additional","affiliation":[{"name":"Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group , Collegeville, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W","family":"Pride","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Vaccines , Pearl River, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Jodar","sequence":"additional","affiliation":[{"name":"Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group , Collegeville, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford D","family":"Gessner","sequence":"additional","affiliation":[{"name":"Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group , Collegeville, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"2024011216425864200_jiad379-B1","doi-asserted-by":"crossref","first-page":"e60273","DOI":"10.1371\/journal.pone.0060273","article-title":"Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques","volume":"8","author":"Said","year":"2013","journal-title":"PLoS One"},{"key":"2024011216425864200_jiad379-B2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/thoraxjnl-2019-213725","article-title":"Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013-18","volume":"75","author":"Pick","year":"2020","journal-title":"Thorax"},{"key":"2024011216425864200_jiad379-B3","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/cid\/ciab307","article-title":"The evolution and distribution of pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Spain using a serotype-specific urinary antigen detection test: the CAPA study, 2011-2018","volume":"73","author":"Torres","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024011216425864200_jiad379-B4","author":"CHMP summary of positive opinion for Apexxnar"},{"key":"2024011216425864200_jiad379-B5","author":"CHMP summary of positive opinion for Vaxneuvance"},{"key":"2024011216425864200_jiad379-B6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","article-title":"Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. Adults: updated recommendations of the advisory committee on immunization practices\u2014United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024011216425864200_jiad379-B7","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00262-17","article-title":"Development of an extended-specificity multiplex immunoassay for detection of streptococcus pneumoniae serotype-specific antigen in urine by use of human monoclonal antibodies","volume":"24","author":"Eletu","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"2024011216425864200_jiad379-B8","first-page":"e430","article-title":"Qualification and clinical validation of an immunodiagnostic assay for detecting 11 additional streptococcus pneumoniae serotype-specific polysaccharides in human urine","volume":"71","author":"Kalina","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024011216425864200_jiad379-B9","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1128\/CVI.00064-12","article-title":"Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine","volume":"19","author":"Pride","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"2024011216425864200_jiad379-B10","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00114-22","article-title":"Development and validation of a sensitive and robust multiplex antigen capture assay to quantify streptococcus pneumoniae serotype-specific capsular polysaccharides in urine","volume":"7","author":"Rajam","year":"2022","journal-title":"mSphere"},{"key":"2024011216425864200_jiad379-B11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1099\/jmm.0.023150-0","article-title":"Development of a sensitive, multiplexed immunoassay using xMAP beads for detection of serotype-specific Streptococcus pneumoniae antigen in urine samples","volume":"60","author":"Sheppard","year":"2011","journal-title":"J Med Microbiol"},{"key":"2024011216425864200_jiad379-B12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02432-2021","article-title":"A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany","volume":"59","author":"Bahrs","year":"2022","journal-title":"Eur Respir J"},{"key":"2024011216425864200_jiad379-B13","author":"Theilacker","year":"2020"},{"key":"2024011216425864200_jiad379-B14","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/ciab375","article-title":"Expanded analysis of 20 pneumococcal serotypes associated with radiographically confirmed community-acquired pneumonia in hospitalized US adults","volume":"73","author":"Isturiz","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024011216425864200_jiad379-B15","doi-asserted-by":"crossref","first-page":"S754","DOI":"10.1093\/ofid\/ofz360.1891","article-title":"Etiology of community-acquired pneumonia (CAP) in hospitalized Native American adults","volume":"6","author":"Hammitt","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2024011216425864200_jiad379-B16","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2079923","article-title":"Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017\u2014April 2019","volume":"18","author":"Liapikou","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"2024011216425864200_jiad379-B17","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1093\/cid\/ciaa043","article-title":"Characteristics of invasive pneumococcal disease caused by emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in England: a prospective observational cohort study, 2014-2018","volume":"71","author":"Amin-Chowdhury","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024011216425864200_jiad379-B18","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cmi.2019.10.034","article-title":"Emerging non-13-valent pneumococcal conjugate vaccine (PCV13) serotypes causing adult invasive pneumococcal disease in the late-PCV13 period in Spain","volume":"26","author":"Gonzalez-Diaz","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2024011216425864200_jiad379-B19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1473-3099(18)30052-5","article-title":"Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study","volume":"18","author":"Ladhani","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2024011216425864200_jiad379-B20","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3390\/microorganisms9051016","article-title":"Invasive pneumococcal disease in adults in Portugal: the importance of serotypes 8 and 3 (2015-2018)","volume":"9","author":"Silva-Costa","year":"2021","journal-title":"Microorganisms"},{"key":"2024011216425864200_jiad379-B21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220453","article-title":"Limited indirect effects of an infant pneumococcal vaccination program in an aging population","volume":"14","author":"van der Linden","year":"2019","journal-title":"PLoS One"},{"key":"2024011216425864200_jiad379-B22","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/cid\/cit428","article-title":"Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial","volume":"57","author":"Dagan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2024011216425864200_jiad379-B23","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1016\/j.vaccine.2022.05.011","article-title":"Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study","volume":"40","author":"Savulescu","year":"2022","journal-title":"Vaccine"},{"key":"2024011216425864200_jiad379-B24","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1016\/j.vaccine.2019.05.065","article-title":"A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands","volume":"37","author":"Gessner","year":"2019","journal-title":"Vaccine"},{"key":"2024011216425864200_jiad379-B25","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.1016\/j.vaccine.2019.08.059","article-title":"Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: a systematic review and pooled analysis","volume":"37","author":"McLaughlin","year":"2019","journal-title":"Vaccine"},{"key":"2024011216425864200_jiad379-B26","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/cid\/ciab990","article-title":"Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged \u226518 years","volume":"75","author":"Essink","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024011216425864200_jiad379-B27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.vaccine.2021.08.049","article-title":"A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)","volume":"40","author":"Platt","year":"2022","journal-title":"Vaccine"},{"key":"2024011216425864200_jiad379-B28","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"key":"2024011216425864200_jiad379-B29","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1016\/j.vaccine.2019.04.087","article-title":"Pneumococcal epidemiology among US adults hospitalized for community-acquired pneumonia","volume":"37","author":"Isturiz","year":"2019","journal-title":"Vaccine"},{"key":"2024011216425864200_jiad379-B30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.1111","article-title":"Incidence and estimated vaccine effectiveness against hospitalizations for all-cause pneumonia among older US adults who were vaccinated and not vaccinated with 13-valent pneumococcal conjugate vaccine","volume":"5","author":"Hsiao","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024011216425864200_jiad379-B31","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/cid\/ciab1051","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine against medically attended lower respiratory tract infection and pneumonia among older adults","volume":"75","author":"Lewnard","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024011216425864200_jiad379-B32","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01874-17","article-title":"Accuracy of high-throughput nanofluidic PCR-based pneumococcal serotyping and quantification assays using sputum samples for diagnosing vaccine serotype pneumococcal pneumonia: analyses by composite diagnostic standards and Bayesian latent class models","volume":"56","author":"Kakiuchi","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2024011216425864200_jiad379-B33","doi-asserted-by":"crossref","first-page":"S956","DOI":"10.1093\/ofid\/ofz360.2395","article-title":"2718. Effectiveness of 13-valent pneumococcal conjugate vaccine in US adults hospitalized with pneumonia, 2014\u20132017","volume":"6","author":"Lessa","year":"2019","journal-title":"Open Forum Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad379\/51684691\/jiad379.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/1\/282\/55572410\/jiad379.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/1\/282\/55572410\/jiad379.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T18:17:03Z","timestamp":1705083423000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/229\/1\/282\/7259336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,9,4]]},"published-print":{"date-parts":[[2024,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad379","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,15]]},"published":{"date-parts":[[2023,9,4]]}}}